Track topics on Twitter Track topics that are important to you
The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.
Original Article: PARP Inhibitor Plus Chemo Means More PFS in Ovarian CancerNEXT ARTICLE
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...